On the public citation graph

Rare diseases and orphan drugs

0 signed · 209 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1038/nrd3275openalex-snapshot
Rare diseases, orphan drugs and their regulation: questions and misconceptions
inferredcites →https://doi.org/10.1089/hum.2011.2515openalex-snapshot
Orphan Drugs, Big Pharma
inferredcites →https://doi.org/10.17226/12953openalex-snapshot
Rare Diseases and Orphan Products

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5010538openalex-extracted
A Public Vaccine Development Service: Public Service Logic in the Development of the Oxford Astrazeneca Covid-19 Vaccine
inferred← citeshttps://doi.org/10.2139/ssrn.5131122openalex-extracted
RareGen Youth Network Response to Critical Medicines Act
inferred← citeshttps://doi.org/10.1001/jamainternmed.2016.0137openalex-snapshot
Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov
inferred← citeshttps://doi.org/10.1002/9781118354483.ch2openalex-snapshot
Target Identification and Validation
inferred← citeshttps://doi.org/10.1002/9781118511329.ch5openalex-snapshot
Restoring Pharma's Image
inferred← citeshttps://doi.org/10.1002/adfm.202530253openalex-snapshot
Tissue Engineered Human Elastic Cartilage From Primary Auricular Chondrocytes for Ear Reconstruction
inferred← citeshttps://doi.org/10.1002/ajmg.a.38326openalex-snapshot
Drug discovery and development for rare genetic disorders
inferred← citeshttps://doi.org/10.1002/cmdc.202300641openalex-snapshot
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective
inferred← citeshttps://doi.org/10.1002/cpt.2306openalex-snapshot
Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals
inferred← citeshttps://doi.org/10.1002/jcph.1501openalex-snapshot
Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval
inferred← citeshttps://doi.org/10.1002/med.21487openalex-snapshot
Evolutionary and genetic features of drug targets
inferred← citeshttps://doi.org/10.1007/978-3-030-77052-5_13openalex-snapshot
Induced Pluripotent Stem Cells in Pediatric Research and Clinical Translation
inferred← citeshttps://doi.org/10.1007/978-3-030-78605-2_23openalex-snapshot
Integrated Life Cycle Management for Rare and Orphan Products
inferred← citeshttps://doi.org/10.1007/978-3-031-25378-2_13openalex-snapshot
Induzierte pluripotente Stammzellen in der pädiatrischen Forschung und klinischen Umsetzung
inferred← citeshttps://doi.org/10.1007/978-3-319-05392-9_137openalex-snapshot
Orphan Drugs
inferred← citeshttps://doi.org/10.1007/978-3-319-08156-4_26openalex-snapshot
Orphan Drug Legislation with Data Fusion Rules Using Multiple Fingerprints Measurements
inferred← citeshttps://doi.org/10.1007/978-3-319-56148-6_17openalex-snapshot
Revealing the Relationship Between Human Genome Regions and Pathological Phenotypes Through Network Analysis
inferred← citeshttps://doi.org/10.1007/978-3-642-27728-3_137-1openalex-snapshot
Orphan Drugs
inferred← citeshttps://doi.org/10.1007/978-3-642-38643-5_1openalex-snapshot
Why R&D into Rare Diseases Matter
inferred← citeshttps://doi.org/10.1007/978-3-662-59046-1_5openalex-snapshot
Orphan-Arzneimittel
inferred← citeshttps://doi.org/10.1007/978-94-017-9214-1_3openalex-snapshot
Emerging Technologies for Gene Identification in Rare Diseases
inferred← citeshttps://doi.org/10.1007/s00108-019-0578-7openalex-snapshot
Orphan Drugs aus Sicht der Arzneimittelkommission der deutschen Ärzteschaft
inferred← citeshttps://doi.org/10.1007/s00228-018-2457-xopenalex-snapshot
Policies and availability of orphan medicines in outpatient care in 24 European countries
inferred← citeshttps://doi.org/10.1007/s10309-019-0274-6openalex-snapshot
„Orphan drugs“ in der Epileptologie
inferred← citeshttps://doi.org/10.1007/s10551-012-1496-yopenalex-snapshot
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry
inferred← citeshttps://doi.org/10.1007/s10557-021-07149-3openalex-snapshot
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
inferred← citeshttps://doi.org/10.1007/s12539-017-0270-3openalex-snapshot
Rare Diseases: Drug Discovery and Informatics Resource
inferred← citeshttps://doi.org/10.1007/s40265-018-0882-xopenalex-snapshot
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges
inferred← citeshttps://doi.org/10.1007/s40271-023-00648-5openalex-snapshot
Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement Sessions
inferred← citeshttps://doi.org/10.1007/s40495-024-00351-5openalex-snapshot
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
inferred← citeshttps://doi.org/10.1007/s43032-021-00621-3openalex-snapshot
Preimplantation Genetic Testing for Rare Inherited Disease of MMA-CblC: an Unaffected Live Birth
inferred← citeshttps://doi.org/10.1016/b978-0-12-811945-7.00012-9openalex-snapshot
Access to High-Cost Medicines in New Zealand
inferred← citeshttps://doi.org/10.1016/b978-0-12-817663-4.00010-6openalex-snapshot
Special topic
inferred← citeshttps://doi.org/10.1016/b978-0-323-88459-4.00019-5openalex-snapshot
Performing clinical drug trials in children with a rare disease
inferred← citeshttps://doi.org/10.1016/j.bcp.2019.07.002openalex-snapshot
Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate
inferred← citeshttps://doi.org/10.1016/j.clinthera.2015.12.001openalex-snapshot
IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research
inferred← citeshttps://doi.org/10.1016/j.coisb.2017.04.010openalex-snapshot
Drug repositioning beyond the low-hanging fruits
inferred← citeshttps://doi.org/10.1016/j.colsurfb.2015.07.046openalex-snapshot
Micellar carriers for the delivery of multiple therapeutic agents
inferred← citeshttps://doi.org/10.1016/j.cpet.2021.09.009openalex-snapshot
Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities
inferred← citeshttps://doi.org/10.1016/j.drudis.2012.04.011openalex-snapshot
Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010
inferred← citeshttps://doi.org/10.1016/j.drudis.2012.08.009openalex-snapshot
Orphan drugs: the regulatory environment
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.06.012openalex-snapshot
EU marketing authorization review of orphan and non-orphan drugs does not differ
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.08.006openalex-snapshot
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery
inferred← citeshttps://doi.org/10.1016/j.drudis.2014.09.013openalex-snapshot
Finding chemical drugs for genetic diseases
inferred← citeshttps://doi.org/10.1016/j.drudis.2020.04.012openalex-snapshot
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations
inferred← citeshttps://doi.org/10.1016/j.drudis.2021.09.004openalex-snapshot
The past, present, and future of enzyme-based therapies
inferred← citeshttps://doi.org/10.1016/j.drudis.2022.01.013openalex-snapshot
Drug repositioning trends in rare and intractable diseases
inferred← citeshttps://doi.org/10.1016/j.drudis.2022.03.002openalex-snapshot
Orphan drug development: The impact of regulatory and reimbursement frameworks
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104810openalex-snapshot
Challenges and progress in access to rare cancer drugs in China: Insights from clinical trials, availability and affordability
inferred← citeshttps://doi.org/10.1016/j.healthpol.2012.08.023openalex-snapshot
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
inferred← citeshttps://doi.org/10.1016/j.healthpol.2015.01.009openalex-snapshot
Why orphan drug coverage reimbursement decision-making needs patient and public involvement
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2021.102522openalex-snapshot
R&D and market size: Who benefits from orphan drug legislation?
inferred← citeshttps://doi.org/10.1016/j.jneumeth.2019.108533openalex-snapshot
iPSC modeling of rare pediatric disorders
inferred← citeshttps://doi.org/10.1016/j.jval.2015.05.008openalex-snapshot
Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group
inferred← citeshttps://doi.org/10.1016/j.jval.2020.06.020openalex-snapshot
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis
inferred← citeshttps://doi.org/10.1016/j.jval.2022.04.1725openalex-snapshot
Evaluating the Health-Related Quality of Life of the Rare Disease Population in Hong Kong Using EQ-5D 3-Level
inferred← citeshttps://doi.org/10.1016/j.mcp.2018.01.001openalex-snapshot
Modeling rare diseases with induced pluripotent stem cell technology
inferred← citeshttps://doi.org/10.1016/j.phrs.2022.106349openalex-snapshot
Clinical trials of orphan drugs in China over the decade 2012–2022: Opportunities and challenges
inferred← citeshttps://doi.org/10.1016/j.tips.2013.03.004openalex-snapshot
Challenges and opportunities of drug repositioning
inferred← citeshttps://doi.org/10.1016/j.tips.2018.03.003openalex-snapshot
Orphan Drugs and Their Impact on Pharmaceutical Development
inferred← citeshttps://doi.org/10.1016/j.vhri.2014.06.009openalex-snapshot
An Overview of the Orphan Medicines Market in Turkey
inferred← citeshttps://doi.org/10.1016/j.ymgme.2016.09.002openalex-snapshot
Nutritional interventions in primary mitochondrial disorders: Developing an evidence base
inferred← citeshttps://doi.org/10.1017/s0266462323000326openalex-snapshot
A systematic review of economic evaluations for RPE65-mediated inherited retinal disease including HTA assessment of broader value
inferred← citeshttps://doi.org/10.1021/acs.biochem.4c00722openalex-snapshot
Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research
inferred← citeshttps://doi.org/10.1021/ci400457vopenalex-snapshot
Structural and Energetic Analyses of SNPs in Drug Targets and Implications for Drug Therapy
inferred← citeshttps://doi.org/10.1038/clpt.2012.80openalex-snapshot
Quantitative Analysis to Guide Orphan Drug Development
inferred← citeshttps://doi.org/10.1038/nbt.3787openalex-snapshot
Industrializing rare disease therapy discovery and development
inferred← citeshttps://doi.org/10.1038/nrd.2017.194openalex-snapshot
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
inferred← citeshttps://doi.org/10.1038/nrd4539openalex-snapshot
Organs-on-chips at the frontiers of drug discovery
inferred← citeshttps://doi.org/10.1038/s41368-018-0041-yopenalex-snapshot
Dental-craniofacial manifestation and treatment of rare diseases
inferred← citeshttps://doi.org/10.1038/s41431-017-0008-zopenalex-snapshot
The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
inferred← citeshttps://doi.org/10.1038/s41526-022-00224-5openalex-snapshot
Rare diseases and space health: optimizing synergies from scientific questions to care
inferred← citeshttps://doi.org/10.1038/s41598-021-91428-4openalex-snapshot
Drug target gene-based analyses of drug repositionability in rare and intractable diseases
inferred← citeshttps://doi.org/10.1039/9781782624202-00003openalex-snapshot
Definitions, History and Regulatory Framework for Rare Diseases and Orphan Drugs
inferred← citeshttps://doi.org/10.1039/9781782624202-00083openalex-snapshot
Treating Rare Diseases: Business Model for Orphan Drug Development
inferred← citeshttps://doi.org/10.1055/a-1904-4004openalex-snapshot
Kieferorthopädie als Fachdisziplin im Zentrum für Seltene Erkrankungen
inferred← citeshttps://doi.org/10.1057/9781137026552_2openalex-snapshot
Regenerative Medicine at a Global Level: Current Patterns and Global Trends
inferred← citeshttps://doi.org/10.1063/5.0327677openalex-snapshot
AI in hematology: A systematic review of techniques for rare blood disorder detection and treatment
inferred← citeshttps://doi.org/10.1080/03007995.2021.1927689openalex-snapshot
The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs)
inferred← citeshttps://doi.org/10.1080/10410236.2013.800830openalex-snapshot
Cognitive and Affective Uses of a Thoracic Outlet Syndrome Facebook Support Group
inferred← citeshttps://doi.org/10.1080/15592294.2023.2230670openalex-snapshot
Epimutation detection in the clinical context: guidelines and a use case from a new Bioconductor package
inferred← citeshttps://doi.org/10.1080/21678707.2022.2153670openalex-snapshot
Quality of life of patients with acromegaly: comparison of different therapeutic modalities
inferred← citeshttps://doi.org/10.1089/genbio.2023.0033openalex-snapshot
Developing Treatments for Rare Diseases on a Shoestring
inferred← citeshttps://doi.org/10.1093/haschl/qxaf057openalex-snapshot
Evidence available and used by the Food and Drug Administration for the approval of orphan and nonorphan drugs
inferred← citeshttps://doi.org/10.1097/gh9.0000000000000456openalex-snapshot
Enhancing clinical sense in rare disease diagnosis: a cloud computing collaboration approach using google workspace
inferred← citeshttps://doi.org/10.1101/2021.03.08.434311openalex-snapshot
Cancer drug discovery as a low rank tensor completion problem
inferred← citeshttps://doi.org/10.1101/2024.01.22.24301610openalex-snapshot
Estimated genetics prevalence of early-onset Parkinson’s disease caused by PRKN mutations
inferred← citeshttps://doi.org/10.1101/2025.10.27.684810openalex-snapshot
Tissue Engineered Elastic Cartilage-Mimetic Auricular Grafts for Ear Reconstruction
inferred← citeshttps://doi.org/10.1108/17506121111190121openalex-snapshot
Orphan drugs: pricing, reimbursement and patient access
inferred← citeshttps://doi.org/10.1108/ijphm-01-2014-0007openalex-snapshot
Comparative effectiveness research and the rise of orphan indications
inferred← citeshttps://doi.org/10.1111/apce.12341openalex-snapshot
Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly
inferred← citeshttps://doi.org/10.1111/cts.12500openalex-snapshot
Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective
inferred← citeshttps://doi.org/10.1111/cts.12501openalex-snapshot
Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective
inferred← citeshttps://doi.org/10.1111/cts.12667openalex-snapshot
Precision Medicines’ Impact on Orphan Drug Designation
inferred← citeshttps://doi.org/10.1111/ene.14302openalex-snapshot
Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases
inferred← citeshttps://doi.org/10.1111/epi.14037openalex-snapshot
A comprehensive approach to identifying repurposed drugs to treat SCN 8A epilepsy
inferred← citeshttps://doi.org/10.1111/imj.16370openalex-snapshot
The increasing costs of medicines and their implications for patients, physicians and the health system
inferred← citeshttps://doi.org/10.1111/resp.12498openalex-snapshot
Delayed access to treatments for rare diseases: Who's to blame?
inferred← citeshttps://doi.org/10.1126/sciadv.adg6375openalex-snapshot
AutoCore: A network-based definition of the core module of human autoimmunity and autoinflammation
inferred← citeshttps://doi.org/10.1134/s1068162024605986openalex-snapshot
Gene Therapy Drugs Based on Synthetic Oligonucleotides
inferred← citeshttps://doi.org/10.1145/3359261openalex-snapshot
"I think we know more than our doctors"
inferred← citeshttps://doi.org/10.1146/annurev-pharmtox-010814-124649openalex-snapshot
The Ethics and Economics of Pharmaceutical Pricing
inferred← citeshttps://doi.org/10.1159/000355941openalex-snapshot
Clinical Trial Transparency and Orphan Drug Development: Recent Trends in Data Sharing by the Pharmaceutical Industry
inferred← citeshttps://doi.org/10.1161/circgen.117.001977openalex-snapshot
Druggability of Coronary Artery Disease Risk Loci
inferred← citeshttps://doi.org/10.1161/circulationaha.114.010403openalex-snapshot
Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation
inferred← citeshttps://doi.org/10.1172/jci.insight.95042openalex-snapshot
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
inferred← citeshttps://doi.org/10.1172/jci166884openalex-snapshot
Human intestinal organoids from Cronkhite-Canada syndrome patients reveal link between serotonin and proliferation
inferred← citeshttps://doi.org/10.1177/0883073813495959openalex-snapshot
Clinical Trials in Rare Disease
inferred← citeshttps://doi.org/10.1177/09287329251344056openalex-snapshot
Bayesian sequential decision-making for rare disease clinical trials
inferred← citeshttps://doi.org/10.1177/1359105315626784openalex-snapshot
Psychosocial impact of mast cell disorders: Pilot investigation of a rare and understudied disease
inferred← citeshttps://doi.org/10.1179/1753807612y.0000000026openalex-snapshot
Rare disease-specific social media sites: An opportunity for collaboration
inferred← citeshttps://doi.org/10.1186/1758-2946-6-5openalex-snapshot
The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation
inferred← citeshttps://doi.org/10.1186/s12910-020-0463-xopenalex-snapshot
Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis
inferred← citeshttps://doi.org/10.1186/s12955-020-01572-0openalex-snapshot
Measuring parent proxy-reported quality of life of 11 rare diseases in children in Zhejiang, China
inferred← citeshttps://doi.org/10.1186/s13023-015-0241-xopenalex-snapshot
A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
inferred← citeshttps://doi.org/10.1186/s13023-016-0392-4openalex-snapshot
The availability and affordability of orphan drugs for rare diseases in China
inferred← citeshttps://doi.org/10.1186/s13023-017-0618-0openalex-snapshot
Review of 11 national policies for rare diseases in the context of key patient needs
inferred← citeshttps://doi.org/10.1186/s13023-017-0690-5openalex-snapshot
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
inferred← citeshttps://doi.org/10.1186/s13023-018-0930-3openalex-snapshot
Investigating the landscape of US orphan product approvals
inferred← citeshttps://doi.org/10.1186/s13023-019-1137-yopenalex-snapshot
Rare diseases in China: analysis of 2014–2015 hospitalization summary reports for 281 rare diseases from 96 tertiary hospitals
inferred← citeshttps://doi.org/10.1186/s13023-019-1168-4openalex-snapshot
Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
inferred← citeshttps://doi.org/10.1186/s13023-020-01568-5openalex-snapshot
The urgent need to empower rare disease organizations in China: an interview-based study
inferred← citeshttps://doi.org/10.1186/s13023-020-01587-2openalex-snapshot
Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China
inferred← citeshttps://doi.org/10.1186/s13023-021-01830-4openalex-snapshot
Demographics, in-hospital analysis, and prevalence of 33 rare diseases with effective treatment in Shanghai
inferred← citeshttps://doi.org/10.1186/s13023-021-01901-6openalex-snapshot
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
inferred← citeshttps://doi.org/10.1186/s13023-021-01954-7openalex-snapshot
A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China
inferred← citeshttps://doi.org/10.1186/s13023-021-01963-6openalex-snapshot
Economic burden and health related quality of life of ultra-rare Gaucher disease in China
inferred← citeshttps://doi.org/10.1186/s13023-022-02440-4openalex-snapshot
Current status and trend of clinical development of orphan drugs in China
inferred← citeshttps://doi.org/10.1186/s13023-023-02684-8openalex-snapshot
Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications
inferred← citeshttps://doi.org/10.1186/s13023-023-02881-5openalex-snapshot
Initiatives to promote access to medicines after publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases
inferred← citeshttps://doi.org/10.1186/s13023-025-03590-xopenalex-snapshot
How does a preference-based generic health-related quality of life measure perform in patients with a rare disease? Measurement properties of the EQ-5D-Y proxy version among underage patients with neurofibromatosis type 1
inferred← citeshttps://doi.org/10.1186/s13023-025-04175-4openalex-snapshot
Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983–2022
inferred← citeshttps://doi.org/10.12688/f1000research.5564.1openalex-snapshot
Collaboration for rare disease drug discovery research
inferred← citeshttps://doi.org/10.12688/f1000research.5577.1openalex-snapshot
Collecting rare diseases
inferred← citeshttps://doi.org/10.12927/hcpol.2015.24210openalex-snapshot
A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds
inferred← citeshttps://doi.org/10.1371/journal.pone.0092452openalex-snapshot
Towards the Disease Biomarker in an Individual Patient Using Statistical Health Monitoring
inferred← citeshttps://doi.org/10.1371/journal.pone.0140002openalex-snapshot
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
inferred← citeshttps://doi.org/10.1377/hlthaff.2015.0921openalex-snapshot
Trends In Orphan New Molecular Entities, 1983–2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target
inferred← citeshttps://doi.org/10.14288/1.0135585openalex-snapshot
Families’ experiences with medical research for pediatric rare diseases : a qualitative ethnographic study of parents and children participating in clinical trials for Duchenne muscular dystrophy (DMD)
inferred← citeshttps://doi.org/10.15252/embr.201541048openalex-snapshot
Responsibility and intellectual property in synthetic biology
inferred← citeshttps://doi.org/10.1533/9781908818393.55openalex-snapshot
Characteristics of rare diseases
inferred← citeshttps://doi.org/10.1533/9781908818393.9openalex-snapshot
Orphan drugs and orphan drug legislation
inferred← citeshttps://doi.org/10.1590/1413-812320182310.14762018openalex-snapshot
Redes de tratamento e as associações de pacientes com doenças raras
inferred← citeshttps://doi.org/10.1590/15174522-0215121openalex-snapshot
Doenças raras, drogas órfãs e as políticas para avaliação e incorporação de tecnologias nos sistemas de saúde
inferred← citeshttps://doi.org/10.1590/1678-4685-gmb-2018-0174openalex-snapshot
Clinical research challenges in rare genetic diseases in Brazil
inferred← citeshttps://doi.org/10.18632/oncotarget.13385openalex-snapshot
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
inferred← citeshttps://doi.org/10.21037/tau-20-945openalex-snapshot
Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1000508/v1openalex-snapshot
Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in Brazil
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1090833/v1openalex-snapshot
Rare Disease Curative Care Expenditure- Financing Scheme-Health Provider- Beneficiary Group Analysis — An Empirical Study in Sichuan Province, China
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1606349/v1openalex-snapshot
The clinical assessment of studies on orphan drugs in relation to the EMA’s authorization marketing decisions
inferred← citeshttps://doi.org/10.21203/rs.3.rs-53391/v1openalex-snapshot
The Multiple Stakeholder Approach to Real-world Evidence Generation: the Results of the Jandhyala Method in Observing Expert Consensus on Quality Indicators of Rare Disease Patient Registries (RDRs) by Stakeholder Group
inferred← citeshttps://doi.org/10.21203/rs.3.rs-88844/v1openalex-snapshot
A questionnaire-based study to comprehensively assess the status quo of rare disease patients in China
inferred← citeshttps://doi.org/10.21423/jrs-v04n01p001openalex-snapshot
A Comprehensive Analysis of Factors That Contribute to Conditional Approval and All-Case Surveillance Designations That Subsequently Lead to Shortening of Review Times in Japan
inferred← citeshttps://doi.org/10.21423/jrs-v04n03p007openalex-snapshot
Emerging Growth of Orphan Drugs for Neurological Diseases in Japan: Potential Benefits for Both Patients and Pharmaceutical Companies
inferred← citeshttps://doi.org/10.21428/b2e239dc.381f7d37openalex-snapshot
Orphan Drugs: Understanding the FDA Approval Process
inferred← citeshttps://doi.org/10.2174/1574884713666180604081349openalex-snapshot
Trends of Clinical Trials for Drug Development in Rare Diseases
inferred← citeshttps://doi.org/10.2217/cer.14.34openalex-snapshot
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
inferred← citeshttps://doi.org/10.2217/clp.13.79openalex-snapshot
Treatment of homozygous familial hypercholesterolemia
inferred← citeshttps://doi.org/10.2217/frd-2021-0008openalex-snapshot
Research and Development of Oligonucleotide Therapeutics in Japan for Rare Diseases
inferred← citeshttps://doi.org/10.2478/cer-2018-0018openalex-snapshot
Corporate Social Responsibility (CSR) of Innovative Pharmaceutical Corporations. The Case of BIOGEN
inferred← citeshttps://doi.org/10.3109/10837450.2012.752388openalex-snapshot
A novel approach to sterile pharmaceutical freeze-drying
inferred← citeshttps://doi.org/10.3389/abp.2025.14777openalex-snapshot
The rare disease burden: a multidimensional challenge
inferred← citeshttps://doi.org/10.3389/fmed.2024.1379966openalex-snapshot
Exploring regulatory flexibility to create novel incentives to optimize drug discovery
inferred← citeshttps://doi.org/10.3389/fphar.2022.869842openalex-snapshot
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.3389/fphar.2025.1558987openalex-snapshot
The clinical assessment of studies on orphan drugs in relation to the EMA’s authorization marketing decisions in Europe
inferred← citeshttps://doi.org/10.3389/fpubh.2024.1398803openalex-snapshot
Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China
inferred← citeshttps://doi.org/10.3390/biomedicines12020446openalex-snapshot
Using Liver Organoids as Models to Study the Pathobiology of Rare Liver Diseases
inferred← citeshttps://doi.org/10.3390/biomedicines13123043openalex-snapshot
Analysis Methods for Diagnosing Rare Neurodevelopmental Diseases with Episignatures: A Systematic Review of the Literature
inferred← citeshttps://doi.org/10.3390/ijerph192316330openalex-snapshot
Quality of Life in Children with Prader–Willi Syndrome and the Impact of the Disease on the Functioning of Families
inferred← citeshttps://doi.org/10.3390/ijms22083980openalex-snapshot
Hybrid Materials Based on Magnetic Iron Oxides with Benzothiazole Derivatives: A Plausible Potential Spectroscopy Probe
inferred← citeshttps://doi.org/10.3390/ijms23158725openalex-snapshot
Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)
inferred← citeshttps://doi.org/10.3390/muscles5030060openalex-snapshot
Characterization of Dystrophin-Related Syndromes: Carriers, DMD, and BMD
inferred← citeshttps://doi.org/10.3390/polym10040444openalex-snapshot
Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies
inferred← citeshttps://doi.org/10.38212/2224-6614.3383openalex-snapshot
The impact of The Rare Disease and Orphan Drug Act in Taiwan
inferred← citeshttps://doi.org/10.4018/978-1-6684-7593-5.ch021openalex-snapshot
Emergent First-Time Leadership in Patient Advocacy Organizations
inferred← citeshttps://doi.org/10.4103/ijp.ijp_646_17openalex-snapshot
Orphan drugs: Indian perspective
inferred← citeshttps://doi.org/10.4103/picr.picr_137_21openalex-snapshot
Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020]
inferred← citeshttps://doi.org/10.4155/fmc.14.65openalex-snapshot
The Discovery of Medicines for Rare Diseases
inferred← citeshttps://doi.org/10.53879/id.63.06.16203openalex-snapshot
A NOVEL SYNTHETIC ROUTE TO RACEMIC SOLRIAMFETOL: ADVANCING THERAPIES FOR NARCOLEPSY
inferred← citeshttps://doi.org/10.54112/bcsrj.v2024i1.758openalex-snapshot
FREQUENCY OF TORCH INFECTION AMONG CONGENITAL CATARACT PATIENTS
inferred← citeshttps://doi.org/10.5465/amd.2018.0183openalex-snapshot
Small Numbers, Big Concerns: Practices and Organizational Arrangements in Rare Disease Drug Repurposing
inferred← citeshttps://doi.org/10.5582/bst.2012.v6.2.48openalex-snapshot
Intractable and rare diseases research in Asia
inferred← citeshttps://doi.org/10.5582/irdr.2012.v1.1.3openalex-snapshot
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives
inferred← citeshttps://doi.org/10.5582/irdr.2012.v1.4.161openalex-snapshot
Study and analysis of the state of rare disease research in Shandong Province, China
inferred← citeshttps://doi.org/10.5582/irdr.2019.01090openalex-snapshot
Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosis
inferred← citeshttps://doi.org/10.5582/irdr.2022.01093openalex-snapshot
Incidence and prevalence of 121 rare diseases in China: Current status and challenges: 2022 revision
inferred← citeshttps://doi.org/10.5582/irdr.2023.01111openalex-snapshot
The use of artificial intelligence in the treatment of rare diseases: A scoping review
inferred← citeshttps://doi.org/10.5582/irdr.2024.01062openalex-snapshot
A bibliometric study of rare diseases in English and Chinese databases from 1985 to 2024 based on CiteSpace
inferred← citeshttps://doi.org/10.5582/irdr.2025.01025openalex-snapshot
Characteristics of rare diseases cases: A summary analysis of hospitalized patients at a hospital in Western China from 2015 to 2023
inferred← citeshttps://doi.org/10.5582/irdr.2025.01056openalex-snapshot
Visualization analysis of the use of traditional Chinese medicine in the diagnosis and treatment of rare diseases in mainland China based on CiteSpace
inferred← citeshttps://doi.org/10.56061/fbujohs.1666184openalex-snapshot
The Effect of Telerehabilitation Supported Occupational Therapy Intervention on Participation and Occupational Performance in Rare Diseases
inferred← citeshttps://doi.org/10.5772/intechopen.76997openalex-snapshot
hiPSC-Based Tissue Organoid Regeneration
inferred← citeshttps://doi.org/10.5772/intechopen.88630openalex-snapshot
Rare Disease Advocacy Groups and Their Significance in Diagnosis, Management, Treatment, and Prevention of Rare Diseases
inferred← citeshttps://doi.org/10.6084/m9.figshare.13083171openalex-snapshot
Additional file 1 of The urgent need to empower rare disease organizations in China: an interview-based study
inferred← citeshttps://doi.org/10.6084/m9.figshare.13159199openalex-snapshot
Additional file 1 of Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China
inferred← citeshttps://doi.org/10.6084/m9.figshare.14759786openalex-snapshot
Additional file 2 of Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
inferred← citeshttps://doi.org/10.6084/m9.figshare.15041055openalex-snapshot
Additional file 1 of A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China
inferred← citeshttps://doi.org/10.6084/m9.figshare.15153806openalex-snapshot
Additional file 1 of Economic burden and health related quality of life of ultra-rare Gaucher disease in China
inferred← citeshttps://doi.org/10.6084/m9.figshare.26614231openalex-snapshot
Additional file 1 of Initiatives to promote access to medicines after publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases
inferred← citeshttps://doi.org/10.6084/m9.figshare.26614234openalex-snapshot
Additional file 2 of Initiatives to promote access to medicines after publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases
showing the first 200 of 206 · page through all 206
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.